

LETTERS TO THE EDITOR

3. Pier GB. Molecular mechanisms of bacterial pathogenesis. In: Isselbacher KJ, Braunwald E, Wilson JD, et al. eds. *Harrison's principles of internal medicine*, 13th ed. New York: McGraw-Hill Inc.; 1994:592.
4. *Guideline on validation of the limulus amoebocyte lysate test as an end-product endotoxin test for human and animal parenteral drugs, biological products, and medical devices*. Division of Manufacturing and Product Control (HFN-320). Office of Compliance. Center for Drug Evaluation and Research. Rockville, MD: Food and Drug Administration; December 1987.
5. *The United States pharmacopeia*, 23rd ed. *The national formulary*, 18th ed. Rockville, MD: United States Pharmacopeia Convention, Inc.; 1995.
6. Trissel LA, Davignon JP, Kleinman LM, et al. *NCI investigational drugs pharmaceutical data*. Bethesda, MD: National Cancer Institute; 1988.
7. Cradock JC, Kleinman LM, Rahman A. Evaluation of some pharmaceutical aspects of intrathecal methotrexate sodium, cytarabine and hydrocortisone sodium succinate. *Am J Hosp Pharm* 1978;35:402-406.

Reply: We would like to thank the writer for his interest and comments on our recent paper, "A Difficult Therapeutic Problem with a Nuclear Medicine Solution: A Case Report", published in the September 1995 issue of the *Journal of Nuclear Medicine Technology*. The writer has given an excellent review of the requirements and the need to test radiopharmaceuticals for pyrogens prior to administration.

We did administer the proper dose. Several trials were made to measure the residual ^{32}P in the syringe and needle. The amount of residual radioactive material was determined to be 5% retention after withdrawing into the syringe and reinjected two

times in a mock up tumor volume. If the 5% retention was not accounted for, the patient would have received a dose lower than the intended therapeutic dose. The goal was to deliver sufficient radiation to stop the growth of the tumor. An effort was also made to assure that none of the dose leaked out of the cyst by creating a slightly negative pressure in the cyst to retain the intracavity dose of ^{32}P chromic phosphate suspension.

James H. Corley
George Burke
Medical College of Georgia
School of Medicine
Department of Radiology
Augusta, Georgia